CN120647702A - 药剂、组合物及其相关方法 - Google Patents

药剂、组合物及其相关方法

Info

Publication number
CN120647702A
CN120647702A CN202510741418.6A CN202510741418A CN120647702A CN 120647702 A CN120647702 A CN 120647702A CN 202510741418 A CN202510741418 A CN 202510741418A CN 120647702 A CN120647702 A CN 120647702A
Authority
CN
China
Prior art keywords
compound
insulin
pharmaceutically acceptable
glucose
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510741418.6A
Other languages
English (en)
Chinese (zh)
Inventor
Z-J·蓝
R·鲍尔
A·扬尼库里斯
T·R·耶拉姆雷迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alltech Corp
Original Assignee
Alltech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alltech Corp filed Critical Alltech Corp
Publication of CN120647702A publication Critical patent/CN120647702A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN202510741418.6A 2017-05-19 2018-05-01 药剂、组合物及其相关方法 Pending CN120647702A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762508730P 2017-05-19 2017-05-19
US62/508,730 2017-05-19
PCT/US2018/030371 WO2018212980A1 (en) 2017-05-19 2018-05-01 Pharmaceutical agents, compositions, and methods relating thereto
CN201880027339.7A CN110545822A (zh) 2017-05-19 2018-05-01 药剂、组合物及其相关方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201880027339.7A Division CN110545822A (zh) 2017-05-19 2018-05-01 药剂、组合物及其相关方法

Publications (1)

Publication Number Publication Date
CN120647702A true CN120647702A (zh) 2025-09-16

Family

ID=64274560

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202510741418.6A Pending CN120647702A (zh) 2017-05-19 2018-05-01 药剂、组合物及其相关方法
CN201880027339.7A Pending CN110545822A (zh) 2017-05-19 2018-05-01 药剂、组合物及其相关方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201880027339.7A Pending CN110545822A (zh) 2017-05-19 2018-05-01 药剂、组合物及其相关方法

Country Status (11)

Country Link
US (2) US11014954B2 (enExample)
EP (1) EP3624809A4 (enExample)
JP (1) JP7224303B2 (enExample)
CN (2) CN120647702A (enExample)
AU (1) AU2018269403B2 (enExample)
CA (1) CA3061893A1 (enExample)
NZ (1) NZ758538A (enExample)
RU (1) RU2765286C2 (enExample)
SA (1) SA519410561B1 (enExample)
SG (1) SG11201909932YA (enExample)
WO (1) WO2018212980A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ758538A (en) * 2017-05-19 2025-08-29 Alltech Inc Pharmaceutical agents, compositions, and methods relating thereto

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002305073A1 (en) * 2001-03-22 2002-10-08 Research Foundation Of The City University Of New York Synthesis of selenium-derivatized nucleosides, nucleotides, phosphoramidites, triphosphates and nucleic acids
US20030078232A1 (en) 2001-08-08 2003-04-24 Elfatih Elzein Adenosine receptor A3 agonists
EP1652519A1 (en) 2004-10-28 2006-05-03 Tamie Nasu Seleniferous composition for producing antioxidase in vivo
US20060198906A1 (en) 2005-03-07 2006-09-07 Sami Labs Limited Compositions and Method to Increase Serum Levels of HDL cholesterol and Lower the Risk of Cardiovascular Disease
US20070077238A1 (en) 2005-10-04 2007-04-05 Teo Alex Y Production of organic and inorganic selenium compounds by lactic acid bacteria
ES2358351T3 (es) 2005-10-13 2011-05-09 Cv Therapeutics, Inc. Agonistas del receptor de adenosina a1.
EP2192905A4 (en) 2007-08-29 2010-11-10 Adam Lubin METHOD FOR SELECTIVE THERAPY OF DISEASE
WO2013151975A1 (en) 2012-04-02 2013-10-10 Northeastern University Compositions and methods for the inhibition of methyltransferases
CN114533753A (zh) 2013-03-15 2022-05-27 全技术公司 含硒组合物及其治疗和预防与线粒体功能障碍有关的疾病或病症的应用
AU2014386236B2 (en) * 2014-03-14 2019-07-11 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof
US20160090397A1 (en) 2014-09-30 2016-03-31 Northeastern University Se-Adenosyl-L-Selenohomocysteine Selenoxide As A Modulator Of Methyltransferase And Other Activities
WO2017048252A1 (en) * 2015-09-15 2017-03-23 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof
NZ758538A (en) 2017-05-19 2025-08-29 Alltech Inc Pharmaceutical agents, compositions, and methods relating thereto

Also Published As

Publication number Publication date
EP3624809A4 (en) 2021-03-03
RU2765286C2 (ru) 2022-01-28
RU2019134865A3 (enExample) 2021-06-30
JP2020520904A (ja) 2020-07-16
US11613552B2 (en) 2023-03-28
NZ758538A (en) 2025-08-29
AU2018269403B2 (en) 2025-03-27
JP7224303B2 (ja) 2023-02-17
BR112019022918A2 (pt) 2020-05-26
EP3624809A1 (en) 2020-03-25
CN110545822A (zh) 2019-12-06
SA519410561B1 (ar) 2024-03-06
RU2019134865A (ru) 2021-06-21
SG11201909932YA (en) 2019-11-28
CA3061893A1 (en) 2018-11-22
US20200123191A1 (en) 2020-04-23
WO2018212980A1 (en) 2018-11-22
US11014954B2 (en) 2021-05-25
US20210238216A1 (en) 2021-08-05
AU2018269403A1 (en) 2019-11-14

Similar Documents

Publication Publication Date Title
JP7009053B2 (ja) 有機セレン化合物の組成物およびその使用方法
RU2663127C2 (ru) Селенсодержащие композиции и их применение для лечения и предотвращения заболеваний или состояний, связанных с митохондриальной дисфункцией
Zhao et al. Regulation of cystathionine gamma-lyase/H2S system and its pathological implication
JP2022501331A (ja) 少なくとも１つのグリシン又はその誘導体と、少なくとも１つのｎ−アセチルシステイン又はその誘導体と、少なくとも１つのニコチンアミドリボシド又はｎａｄ＋前駆体と、を使用する組成物及び方法
KR20100080561A (ko) 5-리폭시게나아제 활성화 단백질(ｆｌａｐ) 억제제
US6521645B2 (en) Methods for the treatment and prevention of urinary stone disease
US11613552B2 (en) Pharmaceutical agents, compositions, and methods relating thereto
JP2003519660A (ja) 耐糖能に影響を与える薬剤を調製するための、環状エーテルの使用
HK40017181A (en) Pharmaceutical agents, compositions, and methods relating thereto
CN114521142B (zh) 用于抑制和/或治疗神经退行性疾病和/或其临床病症的组合物和方法
TW202345779A (zh) ｅＮＡＭＰＴ增加劑、沉默調節蛋白活化或表現增強劑、ＮＡＤ＋增加劑、及老化細胞抑制劑
WO2015009883A1 (en) Activators of nad-dependent protein deacteylases and uses thereof
CN110799518B (zh) 钴胺素衍生物及其用于治疗因缺乏维生素b12供应引起的疾病的用途
BR112019022918B1 (pt) Compostos farmacêuticos contendo selênio para modulação do metabolismo da glicose, composições farmacêuticas e seus usos
EP3144001B1 (en) Compositions of selenoorganic compounds and methods of use thereof
JP2015160847A (ja) 小分子のキサンチンオキシダーゼ阻害剤および使用方法
CN119548574B (zh) 地涌金莲提取物在制备降尿酸产品中的应用
US20230346765A1 (en) Methods of treating xanthine oxidase-related diseases with niflumic acid and derivatives thereof
US20150344419A1 (en) Propionic acids, propionic acid esters, and related compounds
US20150297564A1 (en) Method of enhancing glucose-stimulated insulin secretion and of treating type 2 diabetes or hypoglycemia
WO2023193809A1 (zh) Sarm1抑制剂化合物、包含其的药物组合物及其制备方法和用途
TW202430503A (zh) 新穎治療分子
TW202233173A (zh) 包括１５－ＨＥＴｒＥ之醫藥組合物及其使用方法
HK40068410A (en) Chronic kidney disease treatment or prevention method
MXPA96002577A (en) Treatment of arterioesclerosis and xant

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination